Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
After finishing at $7.79 in the prior trading day, Novavax, Inc (NASDAQ: NVAX) closed at $7.9, up 1.41%. In other words, the price has increased by $1.41 from its previous closing price. On the day, 5.43 million shares were traded. NVAX stock price reached its highest trading level at $7.955 during the session, while it also had its lowest trading level at $7.6613.
Ratios:
Our goal is to gain a better understanding of NVAX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.34 and its Current Ratio is at 2.36. In the meantime, Its Debt-to-Equity ratio is 6.07 whereas as Long-Term Debt/Eq ratio is at 5.93.
On August 20, 2025, BofA Securities Downgraded its rating to Underperform which previously was Neutral but kept the price unchanged to $7. On June 17, 2025, Citigroup started tracking the stock assigning a Sell rating and target price of $6.Citigroup initiated its Sell rating on June 17, 2025, with a $6 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 19 ’25 when YOUNG JAMES F bought 10,000 shares for $7.59 per share.
YOUNG JAMES F bought 4,000 shares of NVAX for $24,406 on Apr 14 ’25. On Dec 13 ’24, another insider, King Rachel K., who serves as the Director of the company, sold 4,150 shares for $9.02 each. As a result, the insider received 37,435 and left with 14,770 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVAX now has a Market Capitalization of 1283133824 and an Enterprise Value of 899316992. As of this moment, Novavax,’s Price-to-Earnings (P/E) ratio for their current fiscal year is 3.50. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.09. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.19 while its Price-to-Book (P/B) ratio in mrq is 34.05. Its current Enterprise Value per Revenue stands at 0.834 whereas that against EBITDA is 2.207.
Stock Price History:
The Beta on a monthly basis for NVAX is 2.73, which has changed by -0.3818466 over the last 52 weeks, in comparison to a change of 0.18469036 over the same period for the S&P500. Over the past 52 weeks, NVAX has reached a high of $15.22, while it has fallen to a 52-week low of $5.01. The 50-Day Moving Average of the stock is 5.40%, while the 200-Day Moving Average is calculated to be 3.48%.
Shares Statistics:
The stock has traded on average 6.55M shares per day over the past 3-months and 7129350 shares per day over the last 10 days, according to various share statistics. A total of 162.16M shares are outstanding, with a floating share count of 147.97M. Insiders hold about 8.90% of the company’s shares, while institutions hold 58.80% stake in the company. Shares short for NVAX as of 1755216000 were 38100228 with a Short Ratio of 5.82, compared to 1752537600 on 43083264. Therefore, it implies a Short% of Shares Outstanding of 38100228 and a Short% of Float of 23.54.
Earnings Estimates
At present, 5.0 analysts are actively evaluating the performance of Novavax, Inc (NVAX) in the stock market.The consensus estimate for the next quarter is -$0.42, with high estimates of $0.23 and low estimates of -$1.51.
Analysts are recommending an EPS of between $3.26 and $1.45 for the fiscal current year, implying an average EPS of $2.62. EPS for the following year is -$0.0, with 7.0 analysts recommending between $2.9 and -$1.3.
Revenue Estimates
6 analysts predict $55.63M in revenue for the current quarter. It ranges from a high estimate of $89.8M to a low estimate of $32.55M. As of the current estimate, Novavax, Inc’s year-ago sales were $84.51MFor the next quarter, 6 analysts are estimating revenue of $128.06M. There is a high estimate of $264.9M for the next quarter, whereas the lowest estimate is $60.94M.
A total of 8 analysts have provided revenue estimates for NVAX’s current fiscal year. The highest revenue estimate was $1.21B, while the lowest revenue estimate was $1B, resulting in an average revenue estimate of $1.07B. In the same quarter a year ago, actual revenue was $682.16MBased on 8 analysts’ estimates, the company’s revenue will be $450.24M in the next fiscal year. The high estimate is $1.07B and the low estimate is $271.14M.
